U.S., Feb. 21 -- ClinicalTrials.gov registry received information related to the study (NCT06837272) titled 'A Longitudinal Study to Explore the Impact of Gut Microbiome on Brain Health in Alzheimer's Disease' on Feb. 15.
Brief Summary: Gut microbiota dysfunction is associated with Alzheimer's disease (AD). However, the potential modulatory mechanism remains unclear. Previous studies have shown that gut-derived metabolites short-chain fatty acids (SCFAs) may be the key mediators between gut microbiota and brain, participating in the modulatory pathway "gut microbiota-SCFAs-brain networks". In this project, high-throughput targeted metabolomics technique will be used to explore the differences of SCFAs in the spectrum of AD, including cogni...